Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Investor Relations Conference Call November 26, 2007
12 slides from Simulations Plus's conference presentation, Nov 27, 2007
Slide 1: Investor Relations Conference Call November 26, 2007
Investor Relations Conference Call November 26, 2007
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: Introduction and Welcome
Introduction and Welcome Agenda – Fiscal year 2007 summary – Strategy going forward – Questions and Answers Introduction and Welcome
Slide 4: Fiscal year 2007 financial summary
Gross revenues = $8.86 MM (up over 51%) SG&A = $3.46 MM (39% of sales, down from 51%) R&D = $0.81 MM (up from $0.45 MM) Income Before Income Taxes = $2.6 MM (up 195% from $0.89 MM) – Income tax estimates were too low for the 2 nd and 3rd quarters due to a communication error with last year’s tax acc
Slide 5: Progress: ADMET Predictor/ADMET Modeler
ADMET Predictor/ADMET Modeler – New model to predict binding affinity of potential new drug molecules to HIV integrase was released – Improvements to ADMET Modeler increase speed and model quality – Tighter integration of ADMET Predictor with both GastroPlus (released) and ClassPharmer (nearing rele
Slide 6: Progress - 2: ClassPharmer and DDDPlus
ClassPharmer – Numerous improvements added in response to customer requests – Site license by one of the world’s largest pharmaceutical companies after a short evaluation – Initial molecule design capabilities released earlier this year – Enhanced molecule design capabilities nearing release DDDPlus
Slide 7: Progress - 3: GastroPlus
GastroPlus – Flagship product and biggest money maker – “Gold standard” in the industry, with far more licenses than any competitor – Funded collaboration with a major pharmaceutical company continues to advance the state-of-the-art in this area – Funded collaboration/study contract with one pharmac
Slide 8: Progress - 4: Words+ subsidiary
Words+ subsidiary – New Say-it! SAM PDA-based communication system developed, nearing release (injection molding issues held up project for several months - now resolved) – New vocabularies for SAM communication software developed, nearing release – Microsoft Vista™ versions of our software were dev
Slide 9: Miscellaneous
Life Sciences staff has been expanded and we are currently seeking two more scientists CEO’s employment contract renewed for two years effective September 1 – Salary increased, bonus eliminated at CEO’s request – Net effect is savings of up to $75,000/year CEO purchased airplane and is using it at h
Slide 10: Strategy Going Forward
Expand product line and services – Pharmaceutical software Continue to enhance current products Complete MembranePlus™ (put on hold two years ago) Seek opportunities to partner and/or acquire new products Continue to seek SBIR funds – Pharmaceutical consulting services Expanded Simulation Technologi
Slide 11: Company is strong and growth is expected to continue
Company is strong and growth is expected to continue Product line is first-class, but we’re not sitting still. All products will continue to be enhanced both in response to customer requests and to expand the utility of our products to new users. $4.5 MM in cash and no debt Acquisitions are in the w
Slide 12: Questions?
Questions?
Simulations Plus — Investor Relations Conference Call November 26, 2007 on 6ix